NCT01749202已完成不适用
Effects of Stearidonic Acid-Containing Foods on Eicosapentaenoic Acid Levels in Red Blood Cells and Omega-3 Index
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Solae, LLC
- 入组人数
- 126
- 试验地点
- 2
- 主要终点
- End of treatment EPA level in RBC membranes, expressed as a percent of total RBC membrane fatty acids
研究概览
简要总结
The purpose of this study is to assess the effect of stearidonic acid when used as a food ingredient on eicosapentaenoic enrichment of red blood cell membranes and Omega-3 Index in men and women.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 21 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female, 21 to 65 years of age.
- •BMI) ≥18.00 and <40.00 kg/m
- •No health conditions that would prevent him/her from fulfilling the study requirements as judged by the Investigator on the basis of medical history and routine laboratory test results.
- •Willing to avoid alcohol consumption for 24 h prior to every clinic visit.
- •No plans to change smoking habits during the study period.
- •Willing to maintain a stable body weight, activity level and dietary pattern except for use of the study products, as directed.
- •Understands the study procedures and signs forms providing informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigator.
排除标准
- •Subject has coronary heart disease or a coronary heart disease risk equivalent including any of the following:
- •Diabetes mellitus
- •Clinical signs of atherosclerosis including peripheral arterial disease, abdominal aortic aneurysm, carotid artery disease
- •Presence of multiple risk factors that give a person a greater than 20% chance for developing coronary artery disease within 10 years.
- •Abnormal laboratory test results of clinical significance
- •TG ≥400 mg/dL at visit 1, week -
- •Smokes more than one pack of cigarettes (20 cigarettes) per day.
- •History or presence of clinically important renal, hepatic, pulmonary, biliary, gastrointestinal, neurologic or endocrine disorders that in the judgment of the Investigator, would interfere with the subject's ability to provide informed consent, comply with the study protocol Stable, treated hypothyroidism is allowed.
- •Uncontrolled hypertension
- •Unstable use within four weeks of visit 1 (week -2) of antihypertensive medications or thyroid hormone replacement.
- •Use of any lipid-altering drugs, including statins, bile acid sequestrants, cholesterol absorption inhibitors, fibrates, or prescription formulations of niacin within four weeks of visit 1 (week -2) and throughout the study. If a subject needs to wash off of a drug, he/she will be consented and then asked to return after the four week washout.
- •Use of EPA/DHA from a drug or supplement within four months of visit 1
- •Frequent use (more than twice per month) of any non-study-related EPA/DHA containing enriched foods (such as DHA-enriched eggs) within four months of visit 1, week -2 and avoidance of these enriched foods throughout the study period
- •Use of seeds and oils containing a significant amount of ALA
- •Consumption of fatty fish (salmon, herring, mackerel, albacore tuna, or sardines) more than twice per month
- •Use of any dietary supplement known to alter lipid metabolism
- •Use of any weight-loss medication
- •Use of any weight loss supplement or program within four weeks of visit 1
- •Known allergy or sensitivity to study products or any ingredients of the study products.
- •Subject is unwilling to consume the study products (bars, beverages and capsules) based on results from the taste testing of the study products at visit 1, week -
- •Subject has a history or presence of cancer in the prior two years, except for non-melanoma skin cancer
- •Females who are pregnant, planning to be pregnant during the study period, lactating, or women of childbearing potential who are unwilling to commit to the use of a medically approved form of contraception throughout the study period. The method of contraception must be recorded in the source documentation.
- •Current or recent history of (within 12 months of visit 1, week -2) or strong potential for alcohol or substance abuse. Alcohol abuse will be defined as >14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1 ½ oz distilled spirits).
- •Exposure to any non-registered drug product within 30 days prior to the screening visit (visit 1, week -2).
结局指标
主要结局
End of treatment EPA level in RBC membranes, expressed as a percent of total RBC membrane fatty acids
时间窗: 12 weeks
次要结局
- Omega-3 Index(12 weeks)
- Triglycerides(12 weeks)
- Fasting insulin(12 weeks)
- HOMA (IR) and HOMA (%B)(12 weeks)
- SDA percent of total RBC membrane fatty acids(12 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Stearidonic Acid and Lipid MetabolismLipid Metabolism DisordersNCT01365078Maastricht University Medical Center36
已完成
4 期
Effect of Plant Sterols Esterified to Fish Oil Fatty Acids on Plasma Lipid LevelsDyslipidemiaNCT00441480Enzymotec91
已完成
不适用
Mediterranean Style Diet and Low Glycemic ResponsesInsulin SensitivityNCT03410719Purdue University166
已完成
不适用
The Influence of Dietary Plant Sterols and Plant Stanols on Cholesterol and Plant Sterol Levels in Atheromatous PlaquesAtherosclerosisNCT00737919University of Helsinki30
已完成
不适用
Lipid-lowering Effect of Plant Stanol Ester Yoghurt DrinksHyperlipidemiasDyslipidemiasHypercholesterolemiaNCT02628990Raisio Group155